Chargement en cours...
Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC
The management of anaplastic lymphoma kinase rearranged (ALK+) non-small cell lung cancer (NSCLC) exemplifies the potential of a precision medicine approach to cancer care. The ALK inhibitor crizotinib has led to improved outcomes in the first- and second-line setting; however, toxicities, intracran...
Enregistré dans:
| Publié dans: | Front Med (Lausanne) |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5127851/ https://ncbi.nlm.nih.gov/pubmed/27965961 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2016.00065 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|